Newborn Screening for Lysosomal Storage Disorders: Methodologies for Measurement of Enzymatic Activities in Dried Blood Spots
Open Access
- 21 December 2018
- journal article
- review article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 5 (1), 1
- https://doi.org/10.3390/ijns5010001
Abstract
All worldwide newborn screening (NBS) for lysosomal storage diseases (LSDs) is performed as a first-tier test by measurement of lysosomal enzymatic activities in dried blood spots (DBS). The currently two available methodologies used for measurement of enzymatic activities are tandem mass spectrometry (MS/MS) and digital microfluidics fluorimetry (DMF-F). In this chapter we summarize the workflows for the two platforms. Neither platform is fully automated, but the relative ease of workflow will be dependent upon the specific operation of each newborn screening laboratory on a case-by-case basis. We provide the screen positive rate (the number of below cutoff newborns per 100,000 newborns) from all NBS laboratories worldwide carrying out MS/MS-based NBS of one or more LSDs. The analytical precision of the MS/MS method is higher than that for DMF-F as shown by analysis of a common set of quality control DBS by the Centers for Disease Control and Prevention (CDC). Both the MS/MS and DMF-F platforms enable multiplexing of the LSD enzymes. An advantage of MS/MS over DMF-F is the ability to include assays of enzymatic activities and biomarkers for which no fluorimetric methods exist. Advantages of DMF-F over MS/MS are: (1) simple to use technology with same-day turn-around time for the lysosomal enzymes with the fastest rates compared to MS/MS requiring overnight analytical runs.; (2) the DMF-F instrumentation, because of its simplicity, requires less maintenance than the MS/MS platform.Keywords
Funding Information
- National Institutes of Health (DK067859)
This publication has 32 references indexed in Scilit:
- Taiwan National Newborn Screening Program by Tandem Mass Spectrometry for Mucopolysaccharidoses Types I, II, and VIThe Journal of Pediatrics, 2019
- Newborn Screening for Lysosomal Storage Diseases: Methodologies, Screen Positive Rates, Normalization of Datasets, Second-Tier Tests, and Post-Analysis ToolsInternational Journal of Neonatal Screening, 2018
- Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month ExperienceThe Journal of Pediatrics, 2017
- Multiplex Tandem Mass Spectrometry Enzymatic Activity Assay for Newborn Screening of the Mucopolysaccharidoses and Type 2 Neuronal Ceroid LipofuscinosisClinical Chemistry, 2017
- Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass SpectrometryMolecular Genetics and Metabolism, 2016
- High-Throughput Assay of 9 Lysosomal Enzymes for Newborn ScreeningClinical Chemistry, 2013
- Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in AustriaThe Lancet, 2012
- Digital Microfluidic Platform for Multiplexing Enzyme Assays: Implications for Lysosomal Storage Disease Screening in NewbornsClinical Chemistry, 2011
- New Strategy for the Screening of Lysosomal Storage Disorders: The Use of the Online Trapping-and-Cleanup Liquid Chromatography/Mass SpectrometryAnalytical Chemistry, 2009
- Direct Multiplex Assay of Lysosomal Enzymes in Dried Blood Spots for Newborn ScreeningClinical Chemistry, 2004